PHOENIX, April 23, 2019 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (“Item 9 Labs” or the “Company”), a leader in comfortable cannabis health solutions for the modern consumer, today released the following welcome letter to Item 9 shareholders from Sara Gullickson, CEO.
Dear Item 9 Labs Shareholders,
As we enter Q2, I am taking this opportunity to introduce myself as the new Chief Executive Officer of Item 9 Labs Corp. This appointment is the culmination of many personal goals, and a position where Item 9 Labs shareholders will benefit from the skills and expertise gained throughout my nine-year cannabis career.
This industry is an ever-evolving landscape, a fast-paced environment not for the faint of heart. Early on, it presented a challenging opportunity and a place where I had the potential to make history. My entrepreneurial journey began by winning multiple medical marijuana licenses across more than a dozen state markets, as well as helping to develop regulatory frameworks in the United States, Canada, Europe, and New Zealand. From the beginning I have been a pioneer, building this industry from the ground up. Over the years, I have worked with entrepreneurs from across the country to secure and launch their businesses with a common goal of bringing alternative health solutions to their communities. My experiences have been valuable and rewarding, providing the platform needed to become a key player in the mainstream cannabis conversation.
Research has also played a pivotal role in my business success. I have spent a significant amount of energy in helping to identify future market trends and building synergistic teams which provides me with an invaluable edge over the competition. My company has received multiple offers to be acquired, merge or go public over the years, none of which fit until the opportunity to merge with Item 9 Labs arose. The decision was easy and natural as I found we had a shared mission, vision, and ethics, which are THE key ingredients for success in the cannabis space. As history reflects, the groups who do not stand for something primarily end up with nothing. As part of your leadership team, I will uphold our company ideals, valuing strategy over a “race to the top mentality.”
I foresee a vibrant future for Item 9 Labs, and with that horizon in mind, I would like to share our corporate plans for 2019.
- Market share in six to ten U.S. cannabis markets by end of 2019.
- Identify and pursue the acquisition of up to four cannabis facilities in existing legal cannabis markets.
- Operate, activate, and/or expand existing Item 9 Labs cannabis facilities in Arizona, Nevada, and North Dakota.
- Complete 20,000 square-foot construction of Strive Wellness of Nevada processing facility in Q4.
- Continue expansion of current distribution and sales network.
The Dispensary Permits team, now an Item 9 Labs asset, will oversee license application filings and facility acquisitions. This balance of opportunities will maximize our goals to be cash flow positive since those defined as “application” will be pre-revenue and the opportunities defined as “acquisition” will be existing facilities that are revenue generating.
I look forward to connecting with all of you in the near future. To stay updated on Item 9 Labs' journey and shareholder news, subscribe to our newsletter - welcome.dispensarypermits.com/shareholder-newsletter
Sincerely,
Sara Gullickson
Chief Executive Officer
Item 9 Labs Corp
Gullickson formerly served as CEO and Founder of Dispensary Permits, which was acquired by Item 9 Labs in November 2018. Named to Marijuana Business Magazine’s 2019 Women to Watch list, Gullickson has headlined cannabis tracks at the Real Estate Wealth Expos in Los Angeles and Toronto, as well as other large-scale business events. She turned down multiple offers before developing a partnership with Item 9 Labs.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer. The Company is bringing best of industry practices to markets from coast to coast through cultivation and production, distinctive retail environments, licensing services, and diverse product suites catering to different medical cannabis demographics. Item 9 Labs Corp. is headquartered in Phoenix, Arizona, with medical cannabis operations in multiple U.S. markets.
Item 9 Labs Corp.’s asset portfolio includes Dispensary Permits, Dispensary Templates, and Strive Life. These assets provide services specific to different stakeholder groups. Dispensary Permits is the Company’s consulting firm specializing in strategic license application and compliance. Dispensary Templates, a subdivision of the firm, is a technology platform with an extensive digital library of licensing and business planning resources. Strive Life is a turnkey dispensary model for the retail sector, elevating the patient experience with consistent and superior service, high-end design, and precision-tested products. It is currently being implemented in Arizona and North Dakota.
In addition, Item 9 Labs Corp. is advancing the industry with its dynamic product suites. The Company has created complementary brands Item 9 Labs and Strive Wellness to channel consumer diversity. Propriety delivery platforms include the Apollo Vape and Pod system, as well as a pioneering intra-nasal device. The Company has received multiple accolades for its medical-grade flower and concentrates.
Item 9 Labs Corp. will be managing cultivation, processing, distribution, and dispensary operations in up to ten U.S. markets by the end of 2019. Current facilities include distribution and processing operations Strive Wellness of Ohio and Strive Wellness of Nevada, as well as dispensary Strive Life North Dakota.
For more information, visit Item 9 Labs Corp. at www.Item9labscorp.com.
Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Media Contact:
Neko Catanzaro
Proven Media
Neko@provenmediaservices.com
(401) 484-4980
Investor Contact:
Jeffrey Rassás
Item 9 Labs Corp.
Jeffrey@item9labs.com
(602) 463-4246